The Henri Termeer Legacy, Patient Centricity, and the Future of Rare Disease Innovation

Our second annual Henri Termeer Tribute Episode brings together five leaders whose work reflects - and continues to expand - the legacy of one of biotech’s most influential figures. Henri Termeer transformed rare disease drug development by insisting that science, business, and humanity were inseparable. His belief in patient first innovation reshaped an entire industry and continues to guide the people who knew him best.

In this episode, host Paul Kidwell convenes a powerful conversation with:

• Wendy Erler - SVP, Patient Affairs, Sarepta Therapeutics

• Belinda Termeer - Co-Founder/President, The Termeer Institute

• Daniel Fischer - CEO, Tevard Biosciences

• Ana Maiques - CEO, Neuroelectrics

• Bob Coughlin - Managing Director, JLL/former President, MassBio

Together, they reflect on Henri’s enduring impact on rare disease drug development, the evolution of patient centric leadership, and the responsibility today’s innovators carry forward.